Dyno Therapeutics Emerges With Novartis, Sarepta Deals For Novel AAV Capsids

 
• By Mandy Jackson

Dyno raised $9m in 2018 but came out of stealth mode with deals worth up to $2bn based on its platform using high throughput biology, AI and machine learning to engineer next-generation AAV capsids.

Adeno-associated virus serotype 1. Virus is used as a vector for gene therapy
Dyno's novel AAV capsids could expand gene therapy's reach • Source: Shutterstock

More from Deals

More from Business